BioLight Announces First IOPtiMate™ System Sale in Peru

TEL AVIV (August 13, 2015) - BioLight Life Sciences Investments Ltd. (TASE: BOLT, OTCQX: BLGTY) (“BioLight” or the “Company”), a firm that invests in, manages and commercializes biomedical innovations in ophthalmology and cancer diagnostics, today announced the first sale of the IOPtiMate™ system to a medical center located in Peru.

The IOPtiMate™ system is based on CO2 laser technology that enables the performance of a unique filtration surgery to treat glaucoma without penetrating the inner part of the eyeball, thus allowing for substantial reductions in post-operative complications and use of eye drops compared with alternatives.

Up until recently, the IOPtiMate™ system has been marketed primarily to leading physicians and medical centers in Asia and Europe. These marketing efforts have resulted in recent first sales of the IOPtiMate™ system in Hong Kong, Poland, Hungary and Romania. Moving forward, and in keeping with the Company’s focus on markets with unmet needs for better solutions to treat glaucoma, BioLight is now also negotiating additional distribution agreements in South and Central America.

This press release is being made in accordance with BioLight policy of announcing a first sale in a new territory.